ArticleJournal of clinical medicine2022
Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Cord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trial.Bioengineering (Basel, Switzerland) · 2026Article
- A sequential and synergistic release sacrificial microgels scaffold for endometrial niche reprogramming and fertility restoration.Materials today. Bio · 2026Article
- A platelet-rich plasma-loaded chitosan-based hydrogel for promoting type 2 diabetes wound healing.iScience · 2026Article
- PRP-related biomaterials enhance bone and nerve repair.Materials today. Bio · 2026Review
- Review
- No Long-Term Superiority of Cord-Derived PRP over Autologous PRP in Knee Osteoarthritis: A Prospective Cohort Study.Journal of functional morphology and kinesiology · 2025Article
- The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review.Current pain and headache reports · 2025Review
- Umbilical cord blood-derived platelet-rich plasma as a coating substrate supporting cell adhesion and biological activities of wound healing.European journal of medical research · 2025Article
- Orthobiologic injections for hip osteoarthritis: A systematic review of clinical outcomes.Orthopedic reviews · 2025Article
- Is Umbilical Cord-Derived Platelet-Rich Plasma a Valid Alternative to Conventional Orthobiologics Post-Knee Arthroscopy?Advances in orthopedics · 2025Article
- Application of cord blood-derived platelet-rich plasma in the treatment of diseases.The Journal of international medical research · 2024Review
- Cord blood-derived biologics lead to robust axonal regeneration in benzalkonium chloride-injured mouse corneas by modulating the Il-17 pathway and neuropeptide Y.Molecular medicine (Cambridge, Mass.) · 2024Article
- Human umbilical cord platelet-rich plasma to treat endometrial pathologies: methodology, composition and pre-clinical models.Human reproduction open · 2023Article
- Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.